In blast crisis of CML and in de novo Ph+ ALL, BCR-ABL retains sensitivity to imatinib, but additional genetic abnormalities conferring drug resistance are common. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.